Micromet

Pomerantz is investigating claims on behalf of investors of Micromet, Inc. (“Micromet” or the “Company”) (NASDAQ: MITI) concerning the proposed acquisition of Micromet by Amgen in a cash transaction valued at approximately $1.16 billion.

The investigation concerns whether the Micromet directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the agreement, Micromet shareholders would receive $11.00 per share of common stock held. However, at least one analyst has set a target price of $12.00 per share.

Micromet shareholders seeking more information about this acquisition are advised to contact Gustavo Bruckner, Esq. at gfbruckner [at] pomlaw [dot] com or 212-661-1100 or toll free at 888-476-6529, ext. 302. Shareholders may also contact Rachelle R. Boyle at rrboyle [at] pomlaw [dot] com or 212-661-1100 or 888-476-6529, ext. 237.